AUS
NZ
UK
CA
USA
IND
Highlights
- Tryptamine launches world-first BED trial using IV-infused psilocin
- Study begins recruitment phase in collaboration with Swinburne
- TRP-8803 explores new treatment pathway for eating disorders
Tryptamine Therapeutics (ASX:TYP) has initiated patient recruitment for its groundbreaking clinical trial exploring TRP-8803 as a potential treatment for Binge Eating Disorder (BED). This trial is the first of its kind, assessing the effects of an intravenous psilocin formulation combined with psychotherapy in addressing one of the most prevalent eating disorders.
Though not part of the ASX 200 stocks, Tryptamine’s innovative approach has caught the attention of the broader biotech investment community. This unique study, conducted in partnership with Swinburne University, marks a significant development in the search for alternative therapies to support individuals living with BED — a condition commonly associated with psychological comorbidities such as anxiety, depression, and compulsive behavior.
The open-label trial will enroll a small number of participants in two separate cohorts. Each participant will undergo preparatory psychotherapy followed by two doses of TRP-8803 in a medically supervised environment. This investigational formulation delivers psilocin directly, offering an alternative to conventional oral psilocybin treatments, which can have delayed effects and reduced dosage control.
The study’s core objective is to evaluate the safety, feasibility, and early clinical outcomes of TRP-8803 when used in conjunction with psychotherapy. By leveraging psilocin’s faster onset and better experience management, the trial aims to create a more consistent and controlled treatment experience. Tryptamine has already gathered preliminary positive data from earlier studies conducted in the United States, which showed encouraging signs for further exploration.
With patient screening expected to commence shortly, Tryptamine is progressing confidently toward first dosing within the quarter. The partnership with Swinburne University has enabled the creation of a robust clinical framework, including all necessary governance approvals and protocols.
The outcome of this trial could open the door to more extensive clinical development of TRP-8803 not only for BED but also for other challenging conditions. Tryptamine Therapeutics is also exploring its potential for indications such as fibromyalgia and irritable bowel syndrome, further diversifying its pipeline in the psychedelic-assisted therapy space.
As patient recruitment moves ahead, this trial reinforces Tryptamine’s position at the forefront of innovation in mental health and neurological treatments, offering hope to many seeking new approaches for complex conditions.
